Advertisement

Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series

Published:August 12, 2021DOI:https://doi.org/10.1016/j.ejim.2021.07.016

      Highlights

      • TCZ is an effective treatment option for irAEs secondary to ICI.
      • TCZ seems to be associated with a favorable profile in terms of oncologic outcome.
      • The combination of TCZ and ICI might guarantee the control of both cancer and irAEs.

      Abstract

      Objective

      Research is moving towards a more personalized management of immune-related adverse events (irAEs) due to immune checkpoint inhibitors (ICI). Our objective was to evaluate the efficacy and safety of tocilizumab in the treatment of these clinical manifestations.

      Methods

      A systematic literature review was performed to retrieve data about the use of tocilizumab in the treatment of irAEs. Additionally, data from cancer patients referred to our Immune-related Adverse Event Clinic and treated with tocilizumab were collected.

      Results

      Our literature review identified 20 articles and 11 meeting abstracts. Data about 91 cancer patients who received tocilizumab for the treatment of irAEs were collected. In 85% of cases, this therapy was associated with clinical benefit and no case of disease progression was reported. ICI therapy was continued following irAE onset and biologic therapy initiation in only three patients.
      Five patients developed irAEs upon ICI initiation and were subsequently treated with tocilizumab at our Centre. At a median follow-up of eight months, tocilizumab was safely continued along with ICI in three out of five patients, and an adequate control of irAE was obtained in all cases. No significant adverse reactions to tocilizumab were reported. Only one patient experienced a disease progression 18 months after ICI discontinuation.

      Conclusion

      Both our systematic literature review and case series highlight the efficacy and safety of tocilizumab in the treatment of irAEs. Furthermore, they both support the possibility of a combined approach with tocilizumab and ICI, to guarantee an effective irAEs management without losing the oncologic response.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Brahmer J.
        • Rodriguez-Abreu D.
        • Robinson A.
        • Hui R.
        • Csőszi T.
        • Fülöp A.
        • et al.
        LBA51 - KEYNOTE-024 5-year OS update: first-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%.
        Ann Oncol. 2020; : S1142-S1215
        • Xie W.
        • Huang H.
        • Xiao S.
        • Fan Y.
        • Deng X.
        • Zhang Z.
        Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies.
        Autoimmun Rev. 2020; 19102687
        • Szekanecz Z.
        • Gomez I.
        • Soós B.
        • Bodoki L.
        • Szamosi S.
        • András C.
        • et al.
        Eight pillars of oncorheumatology: Crossroads between malignancies and musculoskeletal diseases.
        Autoimmun Rev. 2020; 19102658
        • Triggianese P.
        • Novelli L.
        • Galdiero M.R.
        • Chimenti M.S.
        • Conigliaro P.
        • Perricone R.
        • et al.
        Immune checkpoint inhibitors-induced autoimmunity: The impact of gender.
        Autoimmun Rev. 2020; 19102590
        • Kostine M.
        • Finckh A.
        • Bingham C.O.
        • Visser K.
        • Leipe J.
        • Schulze-Koops H.
        • Choy E.H.
        • Benesova K.
        • et al.
        EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
        Ann Rheum Dis. 2021; 80: 36-48
        • Brahmer J.
        • Reckamp K.L.
        • Baas P.
        • Crinò L.
        • Eberhardt W.E.E.
        • Poddubskaya E.
        • Antonia S.
        • Pluzanski A.
        • et al.
        Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer.
        N Engl J Med. 2015; 373: 123-135
        • Herbst R.S.
        • Giaccone G.
        • de Marinis F.
        • Reinmuth N.
        • Vergnenegre A.
        • Barrios C.H.
        • Morise M.
        • Felip E.
        • et al.
        Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC.
        N. Engl. J. Med. 2020; https://doi.org/10.1056/nejmoa1917346
        • Borghaei H.
        • Paz-Ares L.
        • Horn L.
        • Spigel D.R.
        • Steins M.
        • Ready N.E.
        • et al.
        Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer.
        N Engl J Med. 2015; 373: 1627-1639
        • Rittmeyer A.
        • Barlesi F.
        • Waterkamp D.
        • Park K.
        • Ciardiello F.
        • von Pawel J.
        • et al.
        Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
        Lancet. 2017; 389: 255-265
        • Barlesi F.
        • Vansteenkiste J.
        • Spigel D.
        • Ishii H.
        • Garassino M.
        • de Marinis F.
        • et al.
        Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
        Lancet Oncol. 2018; 19: 1468-1479
        • Rizvi N.A.
        • Cho B.C.
        • Reinmuth N.
        • Lee K.H.
        • Luft A.
        • Ahn M.J.
        • et al.
        Durvalumab with or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
        JAMA Oncol. 2020; 6: 661-674
        • Planchard D.
        • Reinmuth N.
        • Orlov S.
        • Fischer J.R.
        • Sugawara S.
        • Mandziuk S.
        • et al.
        ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.
        Ann Oncol. 2019; 394: 1929-1939
        • Herbst R.S.
        • Baas P.
        • Kim D.W.
        • Felip E.
        • Pérez-Gracia J.L.
        • Han J.Y.
        • et al.
        Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial.
        Lancet. 2016; 387: 1540-1550
        • Mok T.S.K.
        • Wu Y.L.
        • Kudaba I.
        • Kowalski D.M.
        • Cho B.C.
        • Turna H.Z.
        • et al.
        Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised.
        Lancet. 2019; 393 (open-label, controlled, phase 3 trial): 1819-1830
        • Hellmann M.D.
        • Paz-Ares L.
        • Bernabe Caro R.
        • Zurawski B.
        • Kim S.-W.
        • Carcereny Costa E.
        • et al.
        Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer.
        N Engl J Med. 2019; 381: 2020-2031
        • Allenbach Y.
        • Anquetil C.
        • Manouchehri A.
        • Benveniste O.
        • Lambotte O.
        • Lebrun-Vignes B.
        • et al.
        Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities.
        Autoimmun Rev. 2020; 19102586
        • Terrier B.
        • Humbert S.
        • Preta L.H.
        • Delage L.
        • Razanamahery J.
        • Laurent-Roussel S.
        • et al.
        Risk of scleroderma according to the type of immune checkpoint inhibitors.
        Autoimmun Rev. 2020; 19102596
        • Matas-García A.
        • Milisenda J.C.
        • Selva-O'Callaghan A.
        • Prieto-González S.
        • Padrosa J.
        • Cabrera C.
        • et al.
        Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern.
        Autoimmun Rev. 2020; 19102455
        • Lidar M.
        • Giat E.
        • Garelick D.
        • Horowitz Y.
        • Amital H.
        • Steinberg-Silman Y.
        • et al.
        Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors.
        Autoimmun Rev. 2020; 21: 3389
        • Narváez J.
        • Juarez-López P.
        • LLuch J.
        • Narváez J.A.
        • Palmero R.
        • García del Muro X.
        • et al.
        Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.
        Autoimmun Rev. 2018; 19: 1040-1045
        • Champiat S.
        • Lambotte O.
        • Barreau E.
        • Belkhir R.
        • Berdelou A.
        • Carbonnel F.
        • et al.
        Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper.
        Ann Oncol. 2016; 27: 559-574
        • Brahmer J.R.
        • Lacchetti C.
        • Schneider B.J.
        • Atkins M.B.
        • Brassil K.J.
        • Caterino J.M.
        • et al.
        Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline.
        J Clin Oncol. 2018; 36: 1714-1768
        • Campochiaro C.
        • De Luca G.
        • Cavalli G.
        Letter by campochiaro et al regarding article, “Clinical features, management, and outcomes of immune checkpoint inhibitor–Related cardiotoxicity.
        Circulation. 2018; 137: 2421-2422
        • Haanen J.B.A.G.
        • Carbonnel F.
        • Robert C.
        • Kerr K.M.
        • Peters S.
        • et al.
        Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann. Oncol. 2017; 28: iv119-iv142
        • Moi L.
        • Bouchaab H.
        • Mederos N.
        • Nguyen-Ngoc T.
        • Perreau M.
        • Fenwick C.
        • et al.
        Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor–Related Cholangiohepatitis.
        J Thorac Oncol. 2021; 16: 318-326
        • Ferrara R.
        • Campochiaro C.
        • Garassino M.C.
        Shifting From a “One Size Fits All” to a Tailored Approach for Immune-Related Adverse Events.
        J Thorac Oncol. 2021; 16: 183-186
      1. REMICADE (infliximab) Label - FDA, Https://Www.Accessdata.Fda.Gov/Drugsatfda_docs/Label/2013/103772s5359lbl.Pdf. (n.d.).

        • Thiel J.
        • Rizzi M.
        • Troilo A.
        • Salzer U.
        • Venhoff A.
        • Lorenzetti R.
        • et al.
        B cell repopulation kinetics after rituximab treatment in anca-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. 2017; 19: 101
        • Boleto G.
        • Avouac J.
        • Wipff J.
        • Forien M.
        • Dougados M.
        • Roux C.
        • et al.
        Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study.
        Semin Arthritis Rheum. 2018; 48: 149-154
        • Le R.Q.
        • Li L.
        • Yuan W.
        • Shord S.S.
        • Nie L.
        • Habtemariam B.A.
        • et al.
        FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
        Oncologist. 2018; 23: 943-947
        • Rubbert-Roth A.
        • Sebba A.
        • Brockwell L.
        • Kelman A.
        • Porter-Brown B.
        • Pulley J.
        • et al.
        Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab.
        RMD Open. 2016; 2e000213
        • Smolen J.S.
        • Landewé R.B.M.
        • Bijlsma J.W.J.
        • Burmester G.R.
        • Dougados M.
        • Kerschbaumer A.
        • et al.
        EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
        Ann Rheum Dis. 2020; 79: 685-699
        • Stone J.H.
        • Tuckwell K.
        • Dimonaco S.
        • Klearman M.
        • Aringer M.
        • Blockmans D.
        • et al.
        Trial of Tocilizumab in Giant-Cell Arteritis.
        N Engl J Med. 2017; 377: 317-328
        • Doms J.
        • Prior J.O.
        • Peters S.
        • Obeid M.
        Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis.
        Ann Oncol. 2020; 31: 1273-1275
        • Pirker I.
        • Rubbert-Roth A.
        • von Kempis J.
        • Fehr M.
        • Neumann T.
        Tocilizumab in a patient with newly diagnosed rheumatoid arthritis secondary to checkpoint inhibitor therapy.
        Clin Exp. 2020; 38: 573-574
        • Kim S.T.
        • Tayar J.
        • Trinh V.A.
        • Suarez-Almazor M.
        • Garcia S.
        • Hwu P.
        • et al.
        Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series.
        Ann Rheum Dis. 2017; 76: 2061-2064
        • Saygin D.
        • Bastacky M.
        • Mascara G.
        • Brenner T.L.
        • Oddis C.
        • Moghadam-Kia S.
        • et al.
        Musculoskeletal immune-related adverse events after immune checkpoint inhibitor therapy: Single center experience.
        Arthritis Rheumatol. 2019; 71: 3769-3770
        • Abdel-Wahab N.
        • Tayar J.H.
        • Diab A.
        • Kim S.T.
        • Lu H.
        • Suarez-Almazor M.E.
        Inflammatory arthritis induced by the use of checkpoint inhibitors for immunotherapy of cancer.
        J Immunother. 2017; 5: S2
        • Tucker L.
        • Sacks S.
        • Al-Mossawi H.
        Inflammatory joint disease triggered by immune checkpoint inhibitors.
        Ann Rheum Dis. 2017; 76: 419
        • Aldrich J.
        • Pundole X.
        • Tummala S.
        • Andersen C.
        • Abdel-Wahab N.
        • Palaskas N.
        • et al.
        Immune checkpoint inhibitor-related myositis: a retrospective cohort study.
        Ann Rheum Dis. 2020; 79: 399
        • Ornstein M.
        • Calabrese C.
        • Wood L.S.
        • Kirchner E.
        • Tyler A.
        • Profusek P.
        • et al.
        Rheumatologic adverse events in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
        Kidney Cancer. 2018; 2: S31-S32
        • Horisberger A.
        • La Rosa S.
        • Zurcher J.P.
        • Zimmermann S.
        • Spertini F.
        • Coukos G.
        • et al.
        A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy.
        J Immunother Cancer. 2018; 6: 156
        • Stroud C.R.G.
        • Hegde A.
        • Cherry C.
        • Naqash A.R.
        • Sharma N.
        • Addepalli S.
        • et al.
        Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.
        J Oncol Pharm Pract. 2019; 25: 551-557
        • Reddy C.A.
        • Schneider B.J.
        • Brackett L.M.
        • Tai A.W.
        Nivolumab-induced large-duct cholangiopathy treated with ursodeoxycholic acid and tocilizumab.
        Immunotherapy. 2019; 11: 1527-1531
        • Nagasunder A.
        • Sidana M.
        • Tiger J.
        Immunotherapy-induced pneumonitis refractory to corticosteroid treatment.
        Chest. 2020; 158 (A910): 4S
        • McGonagle D.
        • Bragazzi N.L.
        • Amital H.
        • Watad A.
        Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival.
        Autoimmun Rev. 2020; 19102456
        • Esfahani K.
        • Miller W.H.
        Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade.
        N Engl J Med. 2017; 376: 1989-1991
        • Braaten T.J.
        • Brahmer J.R.
        • Forde P.M.
        • Le D.
        • Lipson E.J.
        • Naidoo J.
        • et al.
        Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation.
        Ann Rheum Dis. 2020; 79: 332-338
        • Roberts J.
        • Smylie M.
        • Walker J.
        • Basappa N.S.
        • Chu Q.
        • Kolinsky M.
        • et al.
        Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor–induced inflammatory arthritis.
        Clin Rheumatol. 2019; 38: 1513-1519
        • Naqash A.R.
        • Yang L.V.
        • Sanderlin E.J.
        • Atwell D.C.
        • Walker P.R.
        Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report.
        Acta Oncol (Madr). 2018; 57: 705-708
        • Laino A.S.
        • Woods D.
        • Vassallo M.
        • Qian X.
        • Tang H.
        • Wind-Rotolo M.
        Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
        J Immunother Cancer. 2020; 8e000842
        • Mooradian M.J.
        • Nasrallah M.
        • Gainor J.F.
        • Reynolds K.L.
        • Cohen J.V.
        • Lawrence D.P.
        Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.
        Semin Arthritis Rheum. 2019; 48: 1127-1132
        • Moreira A.
        • Loquai C.
        • Pföhler C.
        • Kähler K.C.
        • Knauss S.
        • Heppt M.V.
        • et al.
        Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.
        Eur J Cancer. 2019; 106: 12-23
        • Özdemir B.C.
        • Latifyan S.
        • Perreau M.
        • Fenwick C.
        • Alberio L.
        • Waeber G.
        • et al.
        Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis.
        Ann Oncol. 2020; 31: 1775-1778
        • Adashek M.L.
        • Feldman M.
        Cytokine release syndrome resulting from anti-programmed death-1 antibody: Raising awareness among community oncologists.
        J Oncol Pract. 2019; 15: 502-505
        • Lapman S.
        • Whittier W.L.
        • Parikh R.
        • Khanin Y.
        • Bijol V.
        • Wanchoo R.
        • et al.
        Immune checkpoint inhibitor–associated renal amyloid A amyloidosis: A case series and review of the literature.
        J Onco-Nephrology. 2020; 4: 52-58
        • Li Y.
        • Zhou Y.
        • Liu Y.
        • Zhang G.
        • Xiao L.
        • Li N.
        • et al.
        Severe immune-related hyperthermia followed by immune-related pneumonitis with PD-1 inhibitor (sintilimab) in small cell lung cancer: A case report.
        Thorac Cancer. 2021; https://doi.org/10.1111/1759-7714.13967
        • Wang H.
        • Zhao Y.
        • Zhang X.
        • Si X.
        • Song P.
        • Xiao Y.
        • et al.
        Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study.
        Cancer Med. 2021; 10: 188-198
        • Wang H.
        • Tian R.
        • Gao P.
        • Wang Q.
        • Zhang L.
        Tocilizumab for Fulminant Programmed Death 1 Inhibitor–Associated Myocarditis.
        J Thorac Oncol. 2020; 15: e31-e32
        • Yomota M.
        • Mirokuji K.
        • Sakaguchi M.
        • Kitahara Y.
        • Chin F.
        • Setoguchi K.
        • et al.
        A Case of Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer.
        Intern Med. 2021; https://doi.org/10.2169/internalmedicine.5922-20
        • Olivares-Hernández A.
        • Figuero-Pérez L.
        • Amores Martín M.A.
        • Bellido L.
        • Hernández L.
        • Mezquita M.
        • Vidal Tocino del R.
        • et al.
        Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors.
        Case Rep Oncol Med. 2021; 2021: 1-5
        • Verspohl S.H.
        • Holderried T.
        • Behning C.
        • Brossart P.
        • Schäfer V.S.
        Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis.
        Ther Adv Musculoskelet Dis. 2021; 13 (1759720X211006963)
        • Rotz S.J.
        • Leino D.
        • Szabo S.
        • Mangino J.L.
        • Turpin B.K.
        • Pressey J.G.
        Severe cytokine release syndrome in a patient receiving PD-1-directed therapy.
        Pediatr Blood Cancer. 2017; 64
        • Schafer V.S.
        • Verspohl S.H.
        • Holderried T.
        • Behning C.
        • Brossart P.
        Prevalence and therapy of rheumatological adverse events due to immune checkpoint inhibitor therapy.
        Ann Rheum Dis. 2020; 79: 875
        • Slota A.
        • Khan R.
        • Rahman A.
        • Warner E.A.
        Cytokine release syndrome as a rare complication of nivolumab: A case report.
        Blood. 2019; 134: 5630
        • Rausch C.
        • Paul S.
        • Bravo G.
        • Abbour E.
        • Daver N.
        • Alvarado Y.
        • et al.
        Pattern of immune-mediated toxicities in patients with myelodysplastic syndrome (MDS) treated with nivolumab and ipilimumab.
        Blood. 2018; 132: 4367
        • Reid P.
        • Olson D.
        • Gajewski T.
        Assessing the effect of immunosuppressive agents for immune-related adverse event management on tumor response.
        J Clin Oncol. 2020; 38: 3066
        • Sharma N.
        • Stroud C.
        • Walker P.
        • Cherry C.
        • Cherukuri S.
        • Addepalli S.
        • et al.
        Systemic inflammatory response syndrome (SIRS) with immune checkpoint inhibitors.
        J Clin Oncol. 2016; 34: 3061